Background: The objective of this study was to correlate the V617F mutation of the JAK2 gene and the W515 mutation of the MPL gene in patients with chronic myeloproliferative disease (CMPD) with clinical parameters. Patients and Methods: 51 patients were analyzed: 31 with essential thrombocythemia (ET), 20 with polycythemia vera (PV) and 2 with primary myelofibrosis (PMF). 1 patient had unclassifiable CMPD (CMPD-U). 3 patients had overlapping features of ET and PV. Results: 31 patients (14 with PV, 19 with ET, 3 with concomitant ET and PV, and 1 with PMF) showed the JAK2 mutation, and 2 patients with ET the W515 mutation. There were no significant differences in hematocrit at diagnosis in JAK2-nonmutated versus -mutated patients with PV. Also, patients with ET had comparable platelet counts at diagnosis. The mean time from diagnosis to initiation of first therapy was similar for all patients with non-mutated versus mutated JAK2. Patients with ET and mutated JAK2 were significantly older at diagnosis than those with the wildtype gene (65.5 years vs. 54.4 years; p = 0.016). Conclusions: JAK2 V617F or MPL W515 mutations do not seem to correlate with simple clinical parameters. ET patients with wild-type JAK2 were significantly younger at diagnosis.

Keywords:
Chronic myeloproliferative disease, JAK2, MPL515 mutation, Treatment
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.